Ocular mucous membrane pemphigoid with good response to cyclophosphamide

Authors

  • Magaly Brenda Torrico Pérez José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine
  • Ana Laura Costa José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine
  • Mariano Flores José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine
  • Lola Kuperman Wilder José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine
  • Ana Campastri José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine
  • Luciana Cabral Campana José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine
  • Mónica Di Milia José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine
  • Marcelo Label José María Ramos Mejía General Acute Hospital,  City of Buenos Aires, Argentine

DOI:

https://doi.org/10.47196/da.v31i1.2594

Keywords:

mucosal pemphigoid, cicatricial pemphigoid, autoimmune blistering diseases, cyclophosphamide

Abstract

Mucosal pemphigoid is a rare autoimmune blistering disease with a chronic course that can produce scarring sequelae. It is characterized by affecting the mucous membranes and in some cases the skin. The diagnosis is usually a challenge and it must be early to avoid scarring. Early treatment is recommended. We present two cases of ocular mucosal pemphigoid with rapid and satisfactory response to intravenous cyclophosphamide.

Author Biographies

Magaly Brenda Torrico Pérez, José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine

Second-year Dermatology Attending Physician, Dermatology Division

Ana Laura Costa, José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine

Dermatologist, Dermatology Division

Mariano Flores, José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine

Clinical Physician, Third-year Dermatology Student, Dermatology Division

Lola Kuperman Wilder, José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine

Dermatologist, Dermatology Division

Ana Campastri, José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine

Dermatologist, Dermatology Division

Luciana Cabral Campana, José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine

Dermatologist, in charge of the Autoimmune Blistering Diseases and Stomatology Sector, Associate Professor, University of Buenos Aires, Dermatology Division

Mónica Di Milia, José María Ramos Mejía General Acute Hospital, City of Buenos Aires, Argentine

Dermatologist, Autoimmune Blistering Diseases Sector, Dermatology Division

Marcelo Label, José María Ramos Mejía General Acute Hospital,  City of Buenos Aires, Argentine

Dermatologist, Doctor of Medicine, Emeritus Professor of the University of Buenos Aires, Dermatology Division

References

I. Rashid H, Lamberts A, Borradori L, Alberti-Violetti S, et ál. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology. Part I. J Eur Acad Dermatol Venereol. 2021;35:1750–1764.

II. Candiz ME, Forero O, Label M, Di Milia M, et ál. Guía intersocietaria de manejo del penfigoide de las mucosas. SAD 2023. Disponible en: https://sad.org.ar/wp-content/uploads/2023/04/GUIA-INTERSOC.-DE-MANEJO-DE-PENFIGOIDE-DE-LAS-MUCOSAS-corregidas-por-ECOF-28032023-final.pdf.

III. Santi CG, Gripp AC, Roselino AM, Santana Mello D, et ál. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita. Brazilian Society of Dermatology. An Bras Dermatol. 2019;94:33-47.

IV. Kuperman-Wilder L, Bordon MP, Cilio MA, Cabral Campana L, et ál. Penfigoide de las mucosas a lo largo de los años en nuestro Servicio. Dermatol Argent. 2021;27:155-160.

V. Branisteanu DC, Stoleriu G, Branisteanu DE, Boda D, et ál. Ocular cicatricial pemphigoid (Review). Exp Ther Med. 2020;20:3379-3382.

VI. Taurone S, Spoletini M, Ralli M, Gobbi P, et ál. Ocular mucous membrane pemphigoid: a review. Immunol Res. 2019;67:280-289.

VII. Schmidt E, Rashid H, Marzano AV, Lamberts A, et ál. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology. Part II. J Eur Acad Dermatol Venereol. 2021;35:1926-1948.

VIII. Ong HS, Setterfield JF, Minassian DC, Dart JK. Mucous membrane pemphigoid with ocular involvement: the clinical phenotype and its relationship to direct immunofluorescence findings. Ophthalmology. 2018;125:496-504.

IX. Margolis T. Evidence-based insights into the utility of conjunctival biopsy in mucous membrane pemphigoid. Ophthalmology. 2018;125:474-475.

X. Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology. 2004;111:960-965.

XI. Georgoudis P, Sabatino F, Szentmary N, Palioura S, et ál. Ocular mucous membrane pemphigoid: current state of pathophysiology, diagnostics and treatment. Ophthalmol Therapy. 2019;8:5-17.

XII. Leis-Dosil VM, Prats-Caelles I. Manejo práctico de inmunosupresores en dermatología. Actas Dermosifiliogr. 2018;109:24-34.

XIII. Munyangango EM, Le Roux-Villet C, Doan S, Pascal F, et ál. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid. Br J Dermatol. 2013;168:381-390.

XIV. Friedman J, Marcovich A, Kleinmann G, Schattner A. Low-dose pulse intravenous cyclophosphamide for severe ocular cicatricial pemphigoid in elderly patients. Cornea. 2014;33:1066-1070.

XV. Monach PA, Arnold LM, Merckel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases. A data-driven review. Arthritis Rheumatism. 2010;62:9-21.

Downloads

Published

2025-04-04

Issue

Vol. 31 No. 1 (2025): January-April

Section

Original Articles

License

Copyright (c) 2025 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor